Markets
Novo Nordisk Wegovy Pill China Approval: What It Means for NVO Stock and GLP-1 Markets
Novo Nordisk's CEO has confirmed the company will seek regulatory approval for an oral formulation of Wegovy in China in the near term, opening a potential multi-billion-dollar new revenue channel. Here is what traders and investors need to know about the mechanisms, price levels, and market correlations at play.